Transcriptional regulator ERG (ERG)

Transcriptional regulator ERG (ETS-related gene) is a member of the ETS (E26 transformation-specific) family of transcription factors, characterized by a highly conserved DNA-binding domain. It serves as a master regulator in normal physiological processes, including hematopoiesis, angiogenesis, and the maintenance of vascular integrity (1.1.2, 1.2.5). ERG is a prominent oncogene frequently dysregulated through chromosomal translocations, most notably the TMPRSS2-ERG fusion found in approximately 50% of primary prostate cancers (1.1.3, 1.4.2). This fusion places ERG under the control of androgen-responsive elements, leading to its overexpression and subsequent promotion of cell invasion, epithelial-to-mesenchymal transition, and disruption of normal androgen receptor signaling (1.2.2, 1.2.3). Beyond prostate cancer, ERG fusions are critical drivers in Ewing sarcoma (EWS-ERG) and certain leukemias (FUS-ERG) (1.3.2). Although transcription factors are historically challenging to target, current therapeutic development focuses on small-molecule inhibitors that block ERG's interaction with DNA or its co-regulatory proteins, as well as novel targeted protein degradation strategies such as PROTACs and Helicon degraders (1.3.1, 1.4.2).

Other names

ETS transcription factor ERGETS-related genep55erg-3V-Ets Avian Erythroblastosis Virus E26 Oncogene HomologTransforming protein ERGTMPRSS2-ERG fusion proteinEWS-ERG fusion protein

Inhibition of ERG-DNA binding activity, disruption of protein-protein interactions (e.g., with the BAF complex or androgen receptor), targeted protein degradation (PROTACs/Helicon degraders), and splice-switching to induce non-functional variants.